中药治疗高尿酸血症的临床结局与安全性:回顾性真实世界研究
中药使用者痛风性关节炎风险较苯溴马隆使用者降低43%(HR 0.57,95%CI 0.50-0.65),药物性肝损伤风险两组相当(HR 1.18,95%CI 0.93-1.49),提示中药可作为高尿酸血症有前景的辅助治疗。
要点
- 中药较苯溴马隆降低痛风性关节炎风险43%(HR 0.57,95%CI 0.50-0.65)。
- 两组药物性肝损伤风险相当(HR 1.18,95%CI 0.93-1.49)。
核心结论
- 中药使用者改善了高尿酸血症患者的临床结局且安全性良好,可作为有前景的辅助治疗。
研究设计与样本
- 采用倾向性评分匹配的Cox模型估计中药使用与痛风性关节炎关联的风险比,并进行亚组分析和多种敏感性分析。
主要发现
- 中药使用者较苯溴马隆使用者痛风性关节炎风险降低43%(HR 0.57,95%CI 0.50-0.65)。
- 中药使用者与苯溴马隆使用者药物性肝损伤风险相当(HR 1.18,95%CI 0.93-1.49)。
- 亚组分析和敏感性分析结果总体一致。
临床怎么用
- 对于高尿酸血症患者,可考虑将中药作为辅助治疗选择,但需结合患者具体情况个体化决策。
- 使用中药期间应关注药物性肝损伤风险,定期监测肝功能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hyperuricemia (HUA) has become a bothersome health problem that cannot be ignored. An increasing number of patients with HUA seek Chinese herbal medicine (CHM) as an alternative or complementary treatment. However, there was a lack of real-world evidence on the long-term impact of CHM in HUA populations. PURPOSE: This study aimed to explore the clinical outcomes and safety of CHM among individuals with HUA in mainland China. STUDY DESIGN: A population-based, active-comparator new-user designed cohort study of patients with HUA was performed using the Yinzhou Regional Health Care Database (YRHCD). METHODS: A cox model with propensity score matching was applied to estimate the hazard ratio (HR) of the association between the use of CHM and gouty arthritis (GA). Various subgroup analyses and multiple sensitivity analyses were also performed to demonstrate the robustness of results. The secondary outcomes were drug-induced liver injury (DILI) risk and gouty nephropathy (GN) risk. RESULTS: A total of 40 653 patients with HUA were included from the YRHCD between 2015 and 2024, among whom 35 511 participants were CHM users and 5 142 were benzbromarone (BBR) users. In the primary analysis, the incidence of GA was 34.43 per 1 000 person-years for CHM users and 58.00 per 1 000 person-years for BRR users, respectively. CHM users appeared to have a 43 % reduction in risk of developing GA compared with BBR users with an HR of 0.57 [95 %CI 0.50, 0.65]. In addition, there was comparable safety in DILI between CHM users and BBR users (HR 1.18 [95 % CI 0.93, 1.49]). The results were generally consistent in various subgroup analyses and sensitivity analyses. CONCLUSION: CHM users improved clinical outcomes in patients with HUA and was safe, which can be a promising complementary therapy for HUA patients.
引用
- Long Z, Zhao H, Yin Y, et al. Clinical outcomes and safety of Chinese herbal medicine in the treatment of hyperuricemia: A retrospective real-world study. Phytomedicine. 2025. PMID: 40975036. doi:10.1016/j.phymed.2025.157231
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。